Ofatumumab: all 105 studies that test it
Page 1 of 2. Open to participants first (2), then studies with results posted, then the rest; newest registration first within each.
- Ofatumumab in Treatment-Refractory¬ Narcolepsy Type 1RecruitingNCT07871006Phase 1/2
- Ofatumumab in AQP4-IgG Seropositive NMOSDRecruitingNCT05504694Phase 1/2
- Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in ChinaCompletedNCT05199571Phase 4Results posted
- Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.CompletedNCT05084638Phase 4Results posted
- A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With OfatumumabTerminatedNCT04878211Phase 4Results posted
- Exploring the Immune Response to SARS-CoV-2 COVID-19 Vaccines in Patients With Relapsing Multiple Sclerosis (RMS) Treated With OfatumumabCompletedNCT04869358Phase 4Results posted
- A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With OfatumumabCompletedNCT04667117Phase 4Results posted
- 9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT04510220Phase 3Results posted
- A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple SclerosisCompletedNCT04486716Phase 3Results posted
- An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to OfatumumabCompletedNCT04353492Phase 3Results posted
- Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label OfatumumabCompletedNCT03249714Phase 2Results posted
- Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.CompletedNCT02792231Phase 3Results posted
- Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple SclerosisCompletedNCT02792218Phase 3Results posted
- Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus VulgarisTerminatedNCT02613910Phase 3Results posted
- Augmented Berlin-Frankfurt-Munster Therapy Plus Ofatumumab for Young Adults With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaTerminatedNCT02419469Phase 2Results posted
- Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02199184Phase 2Results posted
- A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLLCompletedNCT02135133Phase 2Results posted
- Efficacy and Safety of Ofatumumab in Treatment of Pemphigus VulgarisTerminatedNCT01920477Phase 3Results posted
- Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic LeukemiaCompletedNCT01848145Phase 2Results posted
- Ofatumumab and Fresh Frozen Plasma in Patients With Chronic Lymphocytic LymphomaCompletedNCT01716208Phase 2Results posted
- Ofatumumab as Primary Therapy of Chronic Graft Versus Host DiseaseCompletedNCT01680965Phase 1/2Results posted
- Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP ChemotherapyCompletedNCT01626352Phase 2Results posted
- A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic LeukemiaCompletedNCT01563055Phase 2Results posted
- Intensive Consolidation and Stem Cell Mobilization Therapy Followed by Autologous Stem Cell Transplantation in High-risk Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaCompletedNCT01555541Phase 2Results posted
- Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom MacroglobulinemiaTerminatedNCT01536067Phase 2Results posted
- An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01532700Phase 2Results posted
- Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell LymphomaCompletedNCT01527149Phase 2Results posted
- Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)CompletedNCT01520922Phase 2Results posted
- Ofatumumab and Dinaciclib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or B-Cell Prolymphocytic LeukemiaCompletedNCT01515176Phase 1/2Results posted
- Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)CompletedNCT01497496Phase 2Results posted
- Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLLCompletedNCT01496976Phase 2Results posted
- Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLLTerminatedNCT01465334Phase 2Results posted
- Phase I/II Study of Bendamustine in Combination With Ofatumumab, Carboplatin and EtoposideCompletedNCT01458366Phase 1/2Results posted
- Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple SclerosisCompletedNCT01457924Phase 2Results posted
- Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic LeukemiaCompletedNCT01444716Phase 2Results posted
- Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell TransplantCompletedNCT01437709Phase 2Results posted
- Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell LymphomaTerminatedNCT01397591Phase 2Results posted
- Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic LymphomaCompletedNCT01363128Phase 2Results posted
- Alemtuzumab-Ofatumumab in Previously Untreated Symptomatic Chronic Lymphocytic LeukemiaActive, not recruitingNCT01361711Phase 2Results posted
- Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's LymphomasCompletedNCT01329900Phase 2Results posted
- Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic LeukemiaCompletedNCT01313689Phase 3Results posted
- Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)CompletedNCT01294579Phase 2Results posted
- Ofatumumab for Minimal Residual Disease (MRD) and Maintenance TherapyTerminatedNCT01258933Phase 2Results posted
- GIMEMA CLL0809 Study (BendOfa)CompletedNCT01244451Phase 2Results posted
- Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)CompletedNCT01243190Phase 2Results posted
- Ofatumumab for Initial Systemic Treatment of Indolent B-cell LymphomaCompletedNCT01239394Phase 2Results posted
- Efficacy and Safety Study of PCI-32765 Combine With Ofatumumab in CLLCompletedNCT01217749Phase 1/2Results posted
- Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing TherapyTerminatedNCT01200589Phase 3Results posted
- Ofatumumab and High-dose Methylprednisolone in Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT01191190Phase 2Results posted
- Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin LymphomaCompletedNCT01190449Phase 2Results posted
- Treatment of Chronic Lymphocytic Leukemia in Patients Previously Exposed to RituximabCompletedNCT01123356Phase 2Results posted
- Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After RituximabTerminatedNCT01119794Phase 2Results posted
- Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01113632Phase 2Results posted
- Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)CompletedNCT01108341Phase 2Results posted
- Patients With Relapsed or Refractory Diffuse Large B Cell Non Hodgkin LymphomasTerminatedNCT01078922Phase 2Results posted
- A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic LeukemiaCompletedNCT01077622Phase 2Results posted
- Study of Lenalidomide and Ofatumumab for the Treatment of Relapsed or Refractory Non-Hodgkin's LymphomaCompletedNCT01060384Phase 1/2Results posted
- Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction TherapyTerminatedNCT01039376Phase 3Results posted
- Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01024010Phase 2Results posted
- Ofatumumab and Bendamustine for Previously Treated Chronic Lymphocytic Leukemia (CLL)TerminatedNCT01010568Phase 2Results posted
- Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT01002755Phase 2Results posted
- Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)CompletedNCT00823719Phase 2Results posted
- A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's MacroglobulinemiaCompletedNCT00811733Phase 2Results posted
- Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Patients With B-cell Chronic Lymphocytic Leukemia (CLL)CompletedNCT00802737Phase 4Results posted
- Ofatumumab + Chlorambucil vs Chlorambucil Monotherapy in Previously Untreated Patients With Chronic Lymphocytic LeukemiaTerminatedNCT00748189Phase 3Results posted
- Long-term Efficacy and Safety of Repeated Ofatumumab Treatment Courses in RA Patients Who Previously Received Ofatumumab or Placebo in Trial Hx-CD20-403TerminatedNCT00655824Phase 2Results posted
- Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After TransplantCompletedNCT00622388Phase 2Results posted
- Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to MTX TherapyTerminatedNCT00611455Phase 3Results posted
- Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-α Antagonist TherapyTerminatedNCT00603525Phase 3Results posted
- Ofatumumab (Humax-CD20) With CHOP (Cyclophosphamide,Doxorubicin, Vincristine, Predisolone) in Follicular Lymphoma (FL) PatientsCompletedNCT00494780Phase 2Results posted
- Ofatumumab With Fludarabine and Cyclophosphamide in B-CLL PatientsCompletedNCT00410163Phase 2Results posted
- HuMax-CD20 i(Ofatumumab) n Follicular Lymphoma (FL) Patients Refractory to RituximabCompletedNCT00394836Phase 2Results posted
- HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and AlemtuzumabCompletedNCT00349349Phase 2Results posted
- A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationActive, not recruitingNCT05090371Phase 4
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingNCT04926818Phase 3
- Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMSCompletedNCT04788615Phase 3
- Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MSActive, not recruitingNCT03650114Phase 3
- "MIRO" Molecularly Oriented Immuno-radio-therapyCompletedNCT02710643Phase 2
- Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)CompletedNCT02689141Phase 2
- Buparlisib and Ofatumumab or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaTerminatedNCT02614508Phase 1
- Ofatumumab Versus Rituximab in Children With Steroid and Calcineurin Inhibitor Dependent Idiopathic Nephrotic SyndromeCompletedNCT02394119Phase 2
- Ofatumumab in Children With Drug Resistant Idiopathic Nephrotic SyndromeTerminatedNCT02394106Phase 2
- Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic LeukemiaCompletedNCT02388048Phase 2
- Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic TransplantationCompletedNCT01809847Phase 2
- Assessment of Efficacy and Safety of Front-line Fludarabine, Cyclophoshamide and Ofatumumab Chemoimmunotherapy in Young Patients With Chronic Lymphocytic Leukemia.CompletedNCT01762202Phase 2
- Drug-drug Interaction Study of Ofatumumab With Bendamustine in Subjects With Indolent B-cell Non-Hodgkin's LymphomaCompletedNCT01691807Phase 1
- Trial of Pentostatin Plus Cyclophosphamide With Ofatumumab (PCO) in Older Patients With Chronic Lymphocytic LeukemiaCompletedNCT01681563Phase 2
- Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B PatientsCompletedNCT01613300Phase 2
- Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma PatientsCompletedNCT01481272Phase 2
- Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell TransplantationCompletedNCT01455051Phase 2
- Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic MelanomaCompletedNCT01376713Phase 2
- Combination of Pentostatin, Bendamustine and Ofatumumab for Treatment of Chronic Lymphocytic Leukemia and LymphomaTerminatedNCT01352312Phase 1
- Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT01310101Phase 2
- Ofatumumab In Older Patients With Untreated Low Or Intermediate Risk Indolent B-Cell LymphomasWithdrawnNCT01263418Phase 2
- Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's LymphomaCompletedNCT01195766Phase 2
- Study of Mini-Chop Plus Ofatumumab To Treat Cd 20+ Diffuse Large B-Cell Lymphoma In Patients Aged Over 80 YearsCompletedNCT01195714Phase 2
- Ofatumumab in Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL)CompletedNCT01187303Phase 2
- Study of Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone (CHOP) With Ofatumumab in Patients With Richter's SyndromeCompletedNCT01171378Phase 2
- PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & OfatumumabWithdrawnNCT01131247Phase 2
- Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and OfatumumabTerminatedNCT01125787Phase 2